Literature DB >> 4329627

Corticotropin therapy in myasthenia gravis: effects, indications, and limitations.

T Namba, N G Brunner, M S Shapiro, D Grob.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4329627     DOI： 10.1212/wnl.21.10.1008

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Benefit from adrenocorticotrophin in myasthenia gravis.

Authors:  L A Liversedge; G M Yuill; I M Wilkinson; J A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

Review 2.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

3.  Ventilatory failure in myasthenia gravis.

Authors:  I T Ferguson; R P Murphy; R G Lascelles
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

Review 4.  Corticosteroid Treatment-Resistance in Myasthenia Gravis.

Authors:  Henry J Kaminski; Jordan Denk
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.